Articles On Paradigm Biopharmaceuticals (ASX:PAR)

ASX futures were down 0.43 per cent at 8.30 am AEDT as US indexes landed in the red on Friday. The S&P 500 ended down by half a per cent and the NASDAQ down 1.23 per cent. The Dow Jones ended up 0.12 per cent. In the US, energy w...

  Paul Rennie – Founder and Managing Director – Paradigm Biopharmaceuticals Limited (ASX:PAR) is a global biopharmaceutical company. Its current focus is a drug for the treatment of osteoarthritis.

The S&P/ASX 200 surged back above 7000 on Tuesday, driven by a shift in rhetoric from US Federal Reserve members towards a more dovish stance and signs of easing inflation. The benchmark closed 1% higher at 7040, marking its best one-da...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

  Paradigm Pharmaceuticals phase II study for treatment of knee osteoarthritis reports successful outcome at day 356 Clinical outcomes improvement observed for iPPS twice weekly compared to placebo control Company now intends to proceed wi...

Paradigm Biopharma set to submit application to TGA EMVision uses artificial intelligence simulation   Paradigm to submit TGA application after successful trial Paradigm Biopharmaceuticals (ASX:PAR) jumped 13% this morning after reporting...

Paradigm Biopharma (ASX:PAR) reports injectable pentosan polysulfate has led to a decrease in self-reported pain in osteoarthritis (OA) patients The company says results show iPPS is likely a superior drug compared to other major treatm...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been catching the eye on Tuesday. At one stage today, the ASX healthcare share was up over 18% to 73.5 cents. The Paradigm share price has pulled back a touch since then but re...

Oil prices held steady following a significant surge as Israel indicated that its retaliation against Hamas attacks had just begun, raising concerns of increased instability in the region. The conflict's potential impact on global oil suppl...

Late-stage drug development company Paradigm Biopharmaceuticals (ASX: PAR) has announced positive study data from a Phase 2 clinical trial of injectable pentosan polysulfate sodium (iPPS) for the treatment of acute pain associated with knee...

10 Oct 2023 - A snapshot of the stocks on the move, featuring Atlantic Lithium (ASX:A11), Raiden Resources (ASX:RDN) and Paradigm Biopharmaceuticals (ASX:PAR).

  Atlantic Lithium (AIM:ALL, ASX:A11, OTCQX:ALLIF) receives authorisation to commence the diversion of the transmission lines crossing the Mankessim Licence, moving a step closer to shovel readiness at the Ewoyaa Lithium Project. Shares are...

Stockhead’s Top 10 at shortly-before-11-ish, produced with gritted teeth as, once again, the local council has decided that it needs to pay some drongo to stand outside my house all day waving a leaf blower around while screaming into his c...

Research reports on ASX-listed companies, to download in full. **** –Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=740BB0E6-015D-39AE-7477F8A8DFBEC04C –Millennium Service...

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=628D02C0-B9D8-EA23-2DB35CB4E58A7CBE –AFT Pharmaceuticals ((AFT)) by Edi...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. The benchmark index is currently down 0.15% to 7,235.2 points. Four ASX shares that are falling more than most today are listed below. Hereâ€...

Futures suggest Australian shares will open relatively unchanged in the face of the RBA interest rate decision this afternoon. Here are some ASX-listed companies with news out today: In healthcare, Paradigm Biopharmaceuticals (PAR) h...

Research reports on ASX-listed companies, to download in full. **** –AFT Pharmaceuticals ((AFP)) – Edison Research: https://www.fnarena.com/index.php/download-article/?n=5CCC26AF-A670-63C8-370E356F819BE3C4 –Barrow Handley Global Share Fund...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Paradigm Bio says drug is effective in osteoarthritic dogs HeraMED signed a deal with Fond, a US-based global SaaS platform The first patient has been dosed in Imugene’s clinical trial   Late stage biotech Paradigm Biopharmaceuticals (ASX...

The ASX is set to open lower on Thursday US debt ceiling deal passed to Senate after the House voted 241-187 Crude prices have fallen by another -2.7%   Aussie shares are set to open lower on Thursday after the shock inflation report yest...

Paradigm Biopharma launches clinical trial website to support development program for knee osteoarthritis therapy. MELBOURNE, Australia, May 25, 2023 /PRNewswire/ — With the launch of a new website dedicated to their global clinical trials...

Research reports on ASX-listed companies, to download in full. –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=F863639F-EF2C-E5CB-37099553DD439B58 –AFT Pharmaceuticals ((AFP)) by Edison R...

The ASX closed in the green, despite teetering around midday after RBA Governor Philip Lowe dampened confidence that interest rates may peak. Mr Lowe warned Australians that the pause may be just temporary, and further interest rate hike...

Paradigm Biopharmaceuticals (PAR) claims a trial of its injectable pentosan polysulfate sodium (iPPS) drug shows the treatment may slow disease progression in knee osteoarthritis (OA) The company has reported data from day 168 of its pha...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and slipped into the red. At the time of writing, the benchmark index is down slightly to 7,221.3 points. Four ASX shares that are falling more tha...

Paradigm Biopharma demonstrates efficacy of knee osteoarthritis drug Race Oncology released a third-party report showing the potential for Zantrene Emyria and Aspen Australia have signed an exclusive binding deal   Paradigm Biopharmaceuti...

ASX closes up 0.78%, while XEC rises 1.91% following global markets higher Morningstar warns of possible start of US recession next week spanning 3 quarters, but talk of pause in Aussie rate hikes ‘premature’ Hubify subsidiary Broadland So...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week (and year) in a positive fashion. In afternoon trade, the benchmark index is up 0.55% to 7,057.8 points. Four ASX shares that are climbing more than most today are listed b...

Paradigm Biopharmaceuticals (PAR) receives a notice of allowance from the US Patent and Trademark Office (USPTO) The notification demonstrates PAR’s patent application has been examined and satisfies the requirements for patentability The p...

The ASX is poised to open higher on Wednesday after a rally in New York Oil prices higher as Saudi said OPEC+ wasn’t considering output increase Crypto broker Genesis near bankcruptcy The ASX is set to open higher on Wednesday after a bro...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.6% to 7,184.3 points. Four ASX shares that have failed to follow the market higher today a...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is having a difficult day. In afternoon trade, the biotechnology company’s shares are down 12% to $1.48. This makes the Paradigm share price one of the worst performers on the Al...

Paradigm Pharmaceuticals’ (PAR) CEO, Marco Polizzi, has stepped down from his role after just five months with the companyMr Polizzi will exit the role on February 20, 2023, and Paradigm did not say why he was stepping downParadigm has appo...

Bod Australia returns positive results from Phase 1 trial Paradigm and Impedimed make executive changes Creso Pharma no longer the subject of ASIC investigation Cannabis stock Bod Australia (ASX:BOD) announced positive results from its Ph...

Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A...

Paradigm Biopharmaceuticals (PAR) doses its first subject in the United Kingdom as part of its phase three clinical trial for the treatment of knee osteoarthritisThe first patient has been treated with Paradigm’s injectable pentosan polysul...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a decline. In afternoon trade, the benchmark index is down 0.6% to 6,774.4 points. Four ASX shares that are falling more than most today are listed below. Here’s why th...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Drug development company Paradigm Biopharmaceuticals [ASX:PAR] reported positive results for one of its clinical trials focused on osteoarthritis (OA). The post Paradigm Biopharmaceuticals [ASX:PAR] Spikes in Phase II Trial Results appeared...

Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t...

The S&P/ASX 200 Index (ASX: XJO) is back on form on Tuesday and racing higher. In afternoon trade, the benchmark index is up 2.5% to 6,619.2 points. Four ASX shares that have climbed more than most today are listed below. Here’s why th...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has returned from its trading halt in style. In morning trade, the drug development company’s shares are up 19% to $1.50. Why is the Paradigm share price rocketing higher? Investor...

Small caps slip down 3.3%, and global markets look equally wobbly China’s manufacturing Purchasing Managers’ Index (PMI) actually grew in September  Alchemy Resources draws a ballot for some prospective lithium ground near big names in WA...

As nerves mount for players on both NRL Grand Final sides preparing to line up at Staiudm Australia on Sunday night, it’s worth remembering the myriad enterprises that enable sportspeople to leap higher and kick further – while also tending...

Paradigm Biopharmaceutical (PAR) has flagged a successful safety review of a phase two study of its pentosan polysulfate sodium (PPS) product in mucopolysaccharidosis type VI (MPS-VI) patientsThe company says the safety monitoring physician...

The S&P/ASX All Ordinaries Index (ASX: XAO) closed in the red on Friday, down 1.9% to just below 6,789 points. But as is often the case, a few ASX All Ords shares defied the index and ramped higher today. Let’s take a look. KMD Brand...

Paradigm Biopharmaceuticals (PAR) raises $66 million through a placement and entitlement offer to fund the development of its clinical trialsAdditionally, the money will support business and product development, as well as working capitalTh...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is enjoying a day in the green today after the company announced its yearly financial results for FY22. Shares in the ASX biotech company are up 2.34% at $1.31 in early afternoon t...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.6% to 7,072.6 points. Four ASX shares that have failed to follow the market higher today ar...